HROW Harrow Health Inc.

Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020

Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020

NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific Standard Time to discuss the financial results and recent business developments.

After the close of the market on November 9, 2020, Harrow will issue a press release containing a link to its third quarter 2020 Letter to Stockholders. The Letter to Stockholders will be archived on the Harrow Investor Relations website in the Archives section, along with the preceding letters, all of which can be found by . On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction, an overview of the quarter, and outlook for the business.

Conference Call Details:

  • U.S. callers: (844) 602-0380



  • International callers: (862) 298-0970



  • Audio-only webcast: please click

Conference Call Replay:

A dial in replay of the call will be available until December 9, 2020. The webcast replay will be available until February 09, 2021.

  • U.S. callers: (877) 481-4010, Replay ID: 38433



  • International callers: (919) 882-2331, Replay ID: 38433



  • Webcast: please click

About Harrow Health

Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including , the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in , , and . Harrow also owns Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow Health’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact:

EN
27/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE

Harrow To Report Third Quarter 2025 Financial Results After Market Clo...

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors”...

 PRESS RELEASE

ImprimisRx Announces Leadership Changes

ImprimisRx Announces Leadership Changes Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as Chief Executive Officer and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Mr. Mullery is a senior executive with over 20 years of leadership ex...

 PRESS RELEASE

Harrow to Acquire Melt Pharmaceuticals

Harrow to Acquire Melt Pharmaceuticals NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and ...

 PRESS RELEASE

Harrow Launches Harrow Access for All (HAFA)

Harrow Launches Harrow Access for All (HAFA) HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All (“HAFA”), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications. H...

 PRESS RELEASE

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Harrow Announces Agenda and Speakers for Investor & Analyst Day NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow’s Investor & Analyst Day will include a comprehensive overview of Harrow’s business, featuring presentations from the Company’s leadership t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch